Phase 1b Open-label Study of MK-7162 in Combination with Pembrolizumab (MK-3475) +/- other therapies in Participants with Advanced Solid Tumors
Brief description of study
If you have been diagnosed with advanced or metastatic solid tumors, you may qualify for this Phase I study. The main goal of this study is to test the safety of the investigational drug, MK-7162 given in combination with pembrolizumab for patients with advanced solid tumors.
Clinical Study Identifier: s17-01300
ClinicalTrials.gov Identifier: NCTs17-01300
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
